Varian Medical Systems VAR will acquire Boston Scientific’s BSX portfolio of drug-loadable microsphere and bland embolic bead products. Terms of the transaction were not disclosed.
Boston Scientific’s portfolio of products treat arteriovenous malformations, which is a tangle of abnormal and poorly formed blood vessels and hypervascular tumors. Varian will not acquire any of the Boston Scientific operations, but plans to manufacture and distribute the products.
"This acquisition from Boston Scientific will strengthen Varian's growing position in the high-value interventional oncology segment and is consistent with our long-term strategy to become a global leader in multidisciplinary, integrated cancer solutions," said Dow Wilson, CEO of Varian.
Varian shares were trading down 0.30% at $139.20 Tuesday afternoon.
Related Links:
Karuna Therapeutics Opens Above IPO Price
ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.